Navigation Links
Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries

MEMPHIS, Tenn., Nov. 20 /PRNewswire-FirstCall/ -- Smith & Nephew ( SNN, LSE: SN) Orthopaedics Division is pleased to announce the signing of a technology development contract with the United States Department of Defense that may lead to the creation of a fracture fixation system intended to revolutionize the treatment of the limbs of soldiers who sustain battlefield injuries.

Last year, the Defense Advanced Research Projects Agency (DARPA), the central research and development agency for the U.S. Department of Defense, accepted proposals to create and develop "fracture putty," a dynamic new material that would markedly enhance the healing of soldiers who suffer traumatic wounds in the field of battle. These wounds often lead to secondary fractures and infections, multiple surgeries, long rehabilitation times and, in some cases, amputation.

In particular, injuries sustained from improvised explosive devices (IEDs) are difficult to treat due to the usually significant loss of bone and soft tissue. The fracture putty system is intended to provide substantial support of the injured limb early in the body's natural healing process so the soldier can more quickly participate in physical therapy and thus reduce the risk of further complications. The putty will then resorb - meaning it will dissolve over time, leaving natural healthy bone in its place. Today's standard treatment methods include permanent metal support devices such as plates, rods and bone screws.

Smith & Nephew is the only medical device company chosen to work on this futuristic material. Beyond this initial project, the company may expand the application of the technology to the treatment of other kinds of bone fractures in both military and civilian trauma care.

"Fracture putty represents the ultimate convergence of orthopaedic material science and mechanics, and has the potential to revolutionize the way patients are treated," said DARPA's program manager, Mitchell Zakin, PhD. "If all technical challenges are met, we believe this innovative technology will provide superior clinical outcomes for patients."

"This announcement represents the spirit of innovation that drives Smith & Nephew scientists and engineers," said David Brumfield, vice president of product development in Smith & Nephew Orthopaedics' Trauma franchise. "We will use the full extent of our expertise, ground-breaking material technology and quality manufacturing to create the best possible treatment for those who have been injured while serving our country."

Smith & Nephew's history of orthopaedic trauma innovation includes the introduction of the compression hip screw and intramedullary hip fracture fixation. Additionally, Smith & Nephew was responsible for introducing the ILIZAROV(TM) method of external circular fixation to the United States, which is manifested today in its award winning TAYLOR SPATIAL FRAME(TM) device, a technology currently used to treat complex fractures sustained by US military personal.

About us

Smith & Nephew is a global medical technology business, specialising in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2008 were $3.8 billion.


DARPA is the central research and development organization for the U.S. Department of Defense (DoD). It manages and directs selected basic and applied research and development projects for DoD, and pursues research and technology where risk and payoff are both very high and where success may provide dramatic advances for traditional military roles and missions.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding planned growth in our business and in our trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

SOURCE Smith & Nephew

SOURCE Smith & Nephew
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data: Cholesterol Management Analysis of Upsher-Smiths Slo-Niacin(R) Tablets in Combination with Lipitor(R)
2. Arcadia Resources Names Stephen Goldsmith to Board of Directors
3. FDA approves GlaxoSmithKlines VOTRIENT(TM) for advanced renal cell cancer
4. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
5. GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations
6. GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM)
7. Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
8. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
9. FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmabs ARZERRA(TM) (ofatumumab)
10. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
11. Smithfield Sends Update to Employees on Testing Process at Veracruz Joint Venture
Post Your Comments:
(Date:11/25/2015)...  The total global healthcare industry is expected to grow ... Latin America has the highest projected growth at ... Japan ), is second with growth projected at 11.5%. ... healthcare expenditure. In 2013-2014, total government funded healthcare was nearly ... to 41.2% in 2013-2014. In real terms, out of pocket ...
(Date:11/25/2015)... Nov. 25, 2015  The American Academy of ... (ACOG), and the March of Dimes cheered today,s ... Our Infants Act of 2015 (S.799), which ... newborns born exposed to drugs, such as opioids, ... introduction, all three organizations have worked together leading ...
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has ... it. Surviving Mesothelioma has just posted the findings on the website. Click here ... the cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, ... Table 1-1 ). More than 3.7 billion people under the age of 50 – ... according to WHO's first global estimates of HSV-1 infection . , "The data shocks ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by ... of issues that are presently affecting Americans. Dedicated to providing the world with a ... the subjects consumers focus on, one episode at a time. , In the ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to announce ... (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to ... of twelve colleges and universities in the state of California make the cut. CBD ...
Breaking Medicine News(10 mins):